---
title: "VK2735 in Chronic weight management: Lifestyle and behavioral interventions"
description: "Formulary evidence on VK2735 in Chronic weight management: Lifestyle and behavioral interventions. Topics: USPSTF recommendation for intensive multicomponent behavioral interventions; Magnitude of weight loss with behavior-based interventions; High-intensity comprehensive lifestyle intervention in the AHA/ACC/TOS guideline; Nutrition, physical activity, and behavioral therapy in adults with type 2 diabetes; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/lifestyle-and-behavioral-interventions"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Lifestyle and behavioral interventions

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Lifestyle and Behavioral Interventions

<a id="topic-2.2.2.1.1-1"></a>

### USPSTF recommendation for intensive multicomponent behavioral interventions

> “The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.”
> “Effective intensive behavioral interventions were designed to help participants achieve or maintain a ≥5% weight loss through a combination of dietary changes and increased physical activity”
> “Most interventions lasted for 1 to 2 years, and the majority had ≥12 sessions in the first year”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

<a id="topic-2.2.2.1.1-2"></a>

### Magnitude of weight loss with behavior-based interventions

> “At 12 to 18 months, pooled results showed greater weight loss among intervention participants (−2.39 kg [−5.3 lb] [95% CI, −2.86 to −1.93]; 67 trials [n = 22,065]”
> “The mean absolute change in weight ranged from −0.5 kg (−1.1 lb) to −9.3 kg (−20.5 lb) among intervention groups and from 1.4 kg (3.1 lb) to −5.6 (−12.3 lb) among control groups.”
> “Pooling the trials (9 studies; n = 3140) showed a significant reduction in the risk of developing type 2 diabetes over 1 to 9 years (pooled risk ratio, 0.67 [95% CI, 0.51 to 0.89]”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

<a id="topic-2.2.2.1.1-3"></a>

### High-intensity comprehensive lifestyle intervention in the AHA/ACC/TOS guideline

> “Prescribe on-site, high-intensity (ie, ≥14 sessions in 6 mo) comprehensive weight loss interventions provided in individual or group sessions by a trained interventionist.”
> “In comprehensive lifestyle interventions, overweight/obese individuals typically are prescribed a diet designed to induce an energy deficit of ≥500 kcal/d. This deficit often is sought by prescribing 1200 to 1500 kcal/d for women and 1500 to 1800 kcal/d for men.”
> “produce average weight losses of up to 8 kg in 6 months of frequent (ie, initially weekly) on-site treatment provided by a trained interventionist”

Source: [Jensen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819889/)

<a id="topic-2.2.2.1.1-4"></a>

### Nutrition, physical activity, and behavioral therapy in adults with type 2 diabetes

> “Nutrition, physical activity, and behavioral therapy are recommended for people with type 2 diabetes and overweight or obesity to achieve both weight and health outcome goals.”
> “Interventions including high frequency of counseling (≥16 sessions in 6 months) with focus on nutrition changes, physical activity, and behavioral strategies to achieve a 500–750 kcal/day energy deficit (irrespective of macronutrient composition) should be recommended for weight loss when available.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.1-5"></a>

### Behavioral therapy combined with GLP-1 therapy in the WHO guideline

> “WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.”
> “Both recommendations were graded conditional”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.1.1-6"></a>

### Durability of intensive lifestyle intervention in Look AHEAD

> “After the first year of the intervention, ILI participants lost a mean of 8.6% of initial weight, compared with 0.7% for participants randomly assigned to a usual care group (p<.001), referred to as Diabetes Support and Education (DSE).”
> “When the intervention ended, ILI participants had a mean loss of 6.0%, as measured from randomization, compared to 3.5% for DSE.”
> “Thirty-one percent of ILI and 23.9% of DSE participants gained ≥2% (p<0.001) of EOI weight, while 36.3% and 45.9% of the two groups, respectively, lost ≥2% of EOI weight (p=0.001).”

Source: [Chao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7437140/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
